Other Cancers Analyzing Pelabresib (CPI-0610) + Ruxolitinib for Treatment-Naïve Myelofibrosis Patients Sep 05, 2023
Other Cancers Disease Progression and Leukemic Transformation in Lower-Risk Myelofibrosis Patients Sep 05, 2023
Other Cancers Elotuzumab, an Anti-SLAMF7 Monoclonal Antibody in Patients with Myelofibrosis Sep 05, 2023
Other Cancers Efficiency & Safety of Pelabresib (CPI-0610) Add-On to Ruxolitinib in Myelofibrosis Sep 04, 2023
